Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rojas, I.
Right arrow Articles by Posner, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rojas, I.
Right arrow Articles by Posner, J. B.
Neurology 2000;55:713-715
© 2000 American Academy of Neurology
Brief Communications

Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies

I. Rojas, MD, F. Graus, MD, F. Keime-Guibert, MD, R. Reñé, MD, J. Y. Delattre, MD, J. M. Ramón, MD, J. Dalmau, MD, PhD and J. B. Posner, MD

From the Services of Neurology (Drs. Rojas and Reñé) and Preventive Medicine (Dr. Ramón), Ciutat Sanitaria Universitaria de Bellvitge, Hospitalet, Spain; the Service of Neurology and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS) (Dr. Graus), Hospital Clínic, University of Barcelona, Barcelona, Spain; the Service of Neurology (Drs. Keime-Guibert and Delattre), Hôpital de la Pitié-Salpêtrière, Paris, France; and the Department of Neurology (Dr. Dalmau and Posner), Memorial Sloan Kettering Cancer Center, New York, NY.

Address correspondence and reprint requests to Dr. Francesc Graus, Servei de Neurologia, Hospital Clínic, Villarroel 170, Barcelona 08036, Spain.

The outcome of 34 women with anti-Yo–associated paraneoplastic cerebellar degeneration was reviewed. Three patients had not developed cancer after more than 4 years of follow-up. The only independent predictor for survival was the type of associated tumor (risk ratio, 1.79; 95% CI, 1.02 to 3.12). Median survival was 100 months for patients with breast cancer and 22 for those with gynecologic cancer. Although paraneoplastic cerebellar degeneration leads to the diagnosis of cancer in 63% of the patients, cancer progression was the cause of death in 52%.




This article has been cited by other articles:


Home page
 BMJHome page
P. Fletcher
A woman with ataxia
BMJ, January 28, 2009; 338(jan28_3): b180 - b180.
[Full Text]

Home page
 ThoraxHome page
S Watanabe, J Tanaka, T Ohta, H Yoshizawa, and F Gejyo
Paraneoplastic neurological syndrome and polyglandular autoimmune syndrome type 2 in a case of small cell lung cancer
Thorax, December 1, 2008; 63(12): 1118 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
R Scheid, R Voltz, S Briest, R Kluge, and D Y von Cramon
Clinical insights into paraneoplastic cerebellar degeneration
J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 529 - 530.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. W. de Beukelaar and P. A. S. Smitt
Managing paraneoplastic neurological disorders.
Oncologist, March 1, 2006; 11(3): 292 - 305.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
B. M. Ances, R. Vitaliani, R. A. Taylor, D. S. Liebeskind, A. Voloschin, D. J. Houghton, S. L. Galetta, M. Dichter, A. Alavi, M. R. Rosenfeld, et al.
Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates
Brain, August 1, 2005; 128(8): 1764 - 1777.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
S. Younes-Mhenni, M. F. Janier, L. Cinotti, J. C. Antoine, F. Tronc, V. Cottin, P. J. Ternamian, P. Trouillas, and J. Honnorat
FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes
Brain, October 1, 2004; 127(10): 2331 - 2338.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
F Graus, J Y Delattre, J C Antoine, J Dalmau, B Giometto, W Grisold, J Honnorat, P S. Smitt, C. Vedeler, J J G M Verschuuren, et al.
Recommended diagnostic criteria for paraneoplastic neurological syndromes
J. Neurol. Neurosurg. Psychiatry, August 1, 2004; 75(8): 1135 - 1140.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. Dalmau, F. Graus, A. Villarejo, J. B. Posner, D. Blumenthal, B. Thiessen, A. Saiz, P. Meneses, and M. R. Rosenfeld
Clinical analysis of anti-Ma2-associated encephalitis
Brain, August 1, 2004; 127(8): 1831 - 1844.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S. Vernino, B. P. O'Neill, R. S. Marks, J. R. O'Fallon, and D. W. Kimmel
Immunomodulatory treatment trial for paraneoplastic neurological disorders
Neuro-oncol, January 1, 2004; 6(1): 55 - 62.
[Abstract] [PDF]

Home page
 NEJMHome page
R. B. Darnell and J. B. Posner
Paraneoplastic Syndromes Involving the Nervous System
N. Engl. J. Med., October 16, 2003; 349(16): 1543 - 1554.
[Full Text] [PDF]

Home page
 BrainHome page
S. Shams'ili, J. Grefkens, B. de Leeuw, M. van den Bent, H. Hooijkaas, B. van der Holt, C. Vecht, and P. Sillevis Smitt
Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients
Brain, June 1, 2003; 126(6): 1409 - 1418.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
F. Bernal, S. Shams'ili, I. Rojas, R. Sanchez-Valle, A. Saiz, J. Dalmau, J. Honnorat, P. Sillevis Smitt, and F. Graus
Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease
Neurology, January 28, 2003; 60(2): 230 - 234.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by AAN Enterprises, Inc.